Cargando…

Bioactive Nanoparticles for Cancer Immunotherapy

Currently, immunotherapy is considered to be one of the effective treatment modalities for cancer. All the developments and discoveries in this field up to the recent Nobel Prize add to the interest for research into this vast area of study. Targeting tumor environment as well as the immune system i...

Descripción completa

Detalles Bibliográficos
Autores principales: Poilil Surendran, Suchithra, Moon, Myeong Ju, Park, Rayoung, Jeong, Yong Yeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321368/
https://www.ncbi.nlm.nih.gov/pubmed/30518139
http://dx.doi.org/10.3390/ijms19123877
_version_ 1783385425786699776
author Poilil Surendran, Suchithra
Moon, Myeong Ju
Park, Rayoung
Jeong, Yong Yeon
author_facet Poilil Surendran, Suchithra
Moon, Myeong Ju
Park, Rayoung
Jeong, Yong Yeon
author_sort Poilil Surendran, Suchithra
collection PubMed
description Currently, immunotherapy is considered to be one of the effective treatment modalities for cancer. All the developments and discoveries in this field up to the recent Nobel Prize add to the interest for research into this vast area of study. Targeting tumor environment as well as the immune system is a suitable strategy to be applied for cancer treatment. Usage of nanoparticle systems for delivery of immunotherapeutic agents to the body being widely studied and found to be a promising area of research to be considered and investigated further. Nanoparticles for immunotherapy would be one of the effective treatment options for cancer therapy in the future due to their high specificity, efficacy, ability to diagnose, imaging, and therapeutic effect. Among the many nanoparticle systems, polylactic-co-glycolic acid (PLGA) nanoparticles, liposomes, micelles, gold nanoparticles, iron oxide, dendrimers, and artificial exosomes are widely used for immunotherapy of cancer. Moreover, the combination therapy found to be the more effective way of treating the tumor. Here, we review the current trends in nanoparticle therapy and efficiency of these nanosystems in delivering antigens, adjuvants, therapeutic drugs, and other immunotherapeutic agents. This review summarizes the currently available bioactive nanoparticle systems for cancer immunotherapy.
format Online
Article
Text
id pubmed-6321368
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63213682019-01-07 Bioactive Nanoparticles for Cancer Immunotherapy Poilil Surendran, Suchithra Moon, Myeong Ju Park, Rayoung Jeong, Yong Yeon Int J Mol Sci Review Currently, immunotherapy is considered to be one of the effective treatment modalities for cancer. All the developments and discoveries in this field up to the recent Nobel Prize add to the interest for research into this vast area of study. Targeting tumor environment as well as the immune system is a suitable strategy to be applied for cancer treatment. Usage of nanoparticle systems for delivery of immunotherapeutic agents to the body being widely studied and found to be a promising area of research to be considered and investigated further. Nanoparticles for immunotherapy would be one of the effective treatment options for cancer therapy in the future due to their high specificity, efficacy, ability to diagnose, imaging, and therapeutic effect. Among the many nanoparticle systems, polylactic-co-glycolic acid (PLGA) nanoparticles, liposomes, micelles, gold nanoparticles, iron oxide, dendrimers, and artificial exosomes are widely used for immunotherapy of cancer. Moreover, the combination therapy found to be the more effective way of treating the tumor. Here, we review the current trends in nanoparticle therapy and efficiency of these nanosystems in delivering antigens, adjuvants, therapeutic drugs, and other immunotherapeutic agents. This review summarizes the currently available bioactive nanoparticle systems for cancer immunotherapy. MDPI 2018-12-04 /pmc/articles/PMC6321368/ /pubmed/30518139 http://dx.doi.org/10.3390/ijms19123877 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Poilil Surendran, Suchithra
Moon, Myeong Ju
Park, Rayoung
Jeong, Yong Yeon
Bioactive Nanoparticles for Cancer Immunotherapy
title Bioactive Nanoparticles for Cancer Immunotherapy
title_full Bioactive Nanoparticles for Cancer Immunotherapy
title_fullStr Bioactive Nanoparticles for Cancer Immunotherapy
title_full_unstemmed Bioactive Nanoparticles for Cancer Immunotherapy
title_short Bioactive Nanoparticles for Cancer Immunotherapy
title_sort bioactive nanoparticles for cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321368/
https://www.ncbi.nlm.nih.gov/pubmed/30518139
http://dx.doi.org/10.3390/ijms19123877
work_keys_str_mv AT poililsurendransuchithra bioactivenanoparticlesforcancerimmunotherapy
AT moonmyeongju bioactivenanoparticlesforcancerimmunotherapy
AT parkrayoung bioactivenanoparticlesforcancerimmunotherapy
AT jeongyongyeon bioactivenanoparticlesforcancerimmunotherapy